Successful treatment of epidermal growth factor receptor inhibitor-induced periungual inflammation with adapalene

Case Reports in Dermatology

Volumn 3, Issue 2, 2011, Pages 130-136

  Hachisuka, Junichi ^a,b   Doi, Kazuko ^a   Moroi, Yoichi ^b   Furue, Masutaka ^b  

^a KARATSU RED CROSS HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Anticancer drug; Retinoid; Side effects

Indexed keywords

ADAPALENE; BETAMETHASONE VALERATE; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; ERLOTINIB; GEFITINIB; GEMCITABINE; IRINOTECAN; NAVELBINE;

ADL DISABILITY; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; GEL; HUMAN; LUNG CANCER; LUNG LOBECTOMY; LUNG METASTASIS; PAIN; PAIN ASSESSMENT; PERIUNGUAL INFLAMMATION; PRIORITY JOURNAL; RECTUM CANCER; SKIN INFLAMMATION; SKIN TOXICITY; TREATMENT DURATION;

EID: 80052761828     PISSN: None     EISSN: 16626567     Source Type: Journal    
DOI: 10.1159/000329914     Document Type: Article

References (13)

1. Li T, Pérez-Soler R: Skin toxicities associated with epidermal growth factor receptor inhibitors. Targ Oncol 2009;4:107-119.
2. Hachisuka J, Yunotani S, Shidahara S, Moroi Y, Furue M: Effect of adapalene on cetuximab-induced painful periungual inflammation. J Am Acad Dermatol 2011;64:e20-e21.
3. Laux I, Jain A, Singh S, Agus DB: Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer 2006;94:85-92. (Pubitemid 43088546)
4. Okines A, Cunningham D, Chau I: Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol DOI: 10.1038/nrclinonc.2011.45.
5. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
6. Jost M, Kari C, Rodeck U: The EGF receptor - an essential regulator of multiple epidermal functions. Eur J Dermatol 2000;10:505-510.
7. Lacouture ME: Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;10:803-812. (Pubitemid 44450468)
8. Pomerantz RG, Chirinos RE, Falo Geskin LJ: Acitretin for treatment of EGFR inhibitor-induced cutaneous toxic effects. Arch Dermatol 2008;144:949-950. (Pubitemid 352039757)
9. DeWitt CA, Siroy AE, Stone SP: Acneiform eruptions associated with epidermal growth factor receptortargeted chemotherapy. J Am Acad Dermatol 2007;56:500-505. (Pubitemid 46273854)
10. Gutzmer R, Werfel T, Mao R, Kapp A, Elsner J: Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol 2005;153:849-851. (Pubitemid 41415923)
11. Rittié L, Varani J, Kang S, Voorhees JJ, Fisher GJ: Retinoid-induced epidermal hyperplasia is mediated by epidermal growth factor receptor activation via specific induction of its ligands heparin-binding EGF and amphiregulin in human skin in vivo. J Invest Dermatol 2006;126:732-739.
12. Pasonen-Seppänen SM, Maytin EV, Törrönen KJ, Hyttinen JM, Hascall VC, MacCallum DK, Kultti AH, Jokela TA, Tammi MI, Tammi RH: All-trans retinoic acid-induced hyaluronan production and hyperplasia are partly mediated by EGFR signaling in epidermal keratinocytes. J Invest Dermatol 2008;128:797-807. (Pubitemid 351374294)
13. Ioannides D, Rigopoulos D, Katsambas A: Topical adapalene gel 0.1% versus isotretinoin gel 0.05% in the treatment of acne vulgaris: a randomized open-label clinical trial. Br J Dermatol 2002;147:523-527. (Pubitemid 35015289)